Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Accounts Payable : $64 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Accounts Payable?

Swedish Orphan Biovitrum AB's Accounts Payable for the quarter that ended in Mar. 2024 was $64 Mil.

Swedish Orphan Biovitrum AB's quarterly Accounts Payable increased from Sep. 2023 ($95 Mil) to Dec. 2023 ($100 Mil) but then declined from Dec. 2023 ($100 Mil) to Mar. 2024 ($64 Mil).

Swedish Orphan Biovitrum AB's annual Accounts Payable increased from Dec. 2021 ($61 Mil) to Dec. 2022 ($121 Mil) but then declined from Dec. 2022 ($121 Mil) to Dec. 2023 ($100 Mil).

Swedish Orphan Biovitrum AB Accounts Payable Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Accounts Payable Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

72.20

68.04

61.39

120.64

99.83

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															59.66	86.64	95.18	99.83	64.45

Swedish Orphan Biovitrum AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Swedish Orphan Biovitrum AB Accounts Payable Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).